Helix Biopharma Corp. Announces Frankfurt Market Trading

Helix BioPharma Corp. (TSX: “HBP”) (OTC PINK: HBPCD) (FRANKFURT: HBP0) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has commenced trading on the Frankfurt Boerse under the following:

Trading symbol: HBP0

WKN: A40GN1

ISIN: CA4229102088

 

NR20240910_Frankfurt Market Trading